Reference SummaryYamane T, Dig Dis Sci 1998 Sep;43(9 Suppl):207S-211S

Title

 Inhibitory effects of rebamipide on ENNG-induced duodenal carcinogenesis in mice: a possible strategy for chemoprevention of gastrointestinal cancers.

Authors

 Yamane T; Nakatani H; Matsumoto H; Iwata Y; Kikuoka N; Takahashi T

Journal

 Dig Dis Sci

Volume

 43

Issue

 9 Suppl

Year

 1998

Pages

 207S-211S

Abstract

 Rebamipide is a potent antioxidative agent; it increases gastric mucosal PGE2 production and thus protects the gastric mucosa. We hypothesized that the mechanisms of ulcer formation could be extended to carcinogenesis and that an increase in gastric mucosal protection may result in a decrease in gastric carcinogenesis. Therefore, we assessed the inhibitory effects of rebamipide on N-ethyl-N'-nitro-N- nitrosoguanidine (ENNG) -induced carcinogenesis in mice. The percentage of tumor-bearing mice in three treatment groups--ENNG + rebamipide 20 mg, ENNG + rebamipide 50 mg, and ENNG alone--was 55%, 42%, and 67%, respectively. The incidence of tumorigenesis tended to decrease with increasing doses of rebamipide. The difference between ENNG + rebamipide 50 mg and ENNG alone was statistically significant (P < 0.05). These results suggest that rebamipide may strengthen the host defense mechanisms related to carcinogenesis in the digestive tract.

Links

 J:52691 – MGI References
9753252 – National Library of Medicine/PubMed

Models
Strain Model Name Treatment Agent(s) Organ Affected Frequency Model Details
C57BL/6 Esophagus tumor Esophagus

0
C57BL/6 Esophagus tumor
  • rebamipide
 Esophagus

0
C57BL/6 Esophagus tumor
  • N-ethyl-N'-nitro-N-nitroguanidine (ENNG)
 Esophagus

0
C57BL/6 Esophagus tumor
  • N-ethyl-N'-nitro-N-nitroguanidine (ENNG)
  • rebamipide
 Esophagus

0
C57BL/6 Intestine - Small Intestine - Duodenum adenocarcinoma
  • N-ethyl-N'-nitro-N-nitroguanidine (ENNG)
 Intestine - Small Intestine - Duodenum

67
C57BL/6 Intestine - Small Intestine - Duodenum adenocarcinoma
  • N-ethyl-N'-nitro-N-nitroguanidine (ENNG)
  • rebamipide
 Intestine - Small Intestine - Duodenum

42 - 55
C57BL/6 Intestine - Small Intestine - Duodenum tumor Intestine - Small Intestine - Duodenum

0
C57BL/6 Intestine - Small Intestine - Duodenum tumor
  • rebamipide
 Intestine - Small Intestine - Duodenum

0
C57BL/6 Stomach tumor Stomach

0
C57BL/6 Stomach tumor
  • rebamipide
 Stomach

0
C57BL/6 Stomach tumor
  • N-ethyl-N'-nitro-N-nitroguanidine (ENNG)
 Stomach

0
C57BL/6 Stomach tumor
  • N-ethyl-N'-nitro-N-nitroguanidine (ENNG)
  • rebamipide
 Stomach

0